Oncolytics Biotech, Inc. ONCY

NAS: ONCY | ISIN: CA6823108759   1/05/2025
0,550 USD (-3,64%)
(-3,64%)   1/05/2025

24 april 2025 · Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action · Persbericht

14 april 2025 · With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz · Persbericht

11 april 2025 · Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital · Persbericht

10 april 2025 · Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers · Persbericht

7 maart 2025 · Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 · Persbericht

6 september 2024 · Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September · Persbericht

2 augustus 2024 · Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference · Persbericht

1 augustus 2024 · Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights · Persbericht

24 juli 2024 · Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights · Persbericht

27 juni 2024 · Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program · Persbericht

24 juni 2024 · Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence · Persbericht

20 juni 2024 · Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer · Persbericht

24 mei 2024 · Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action · Persbericht

16 mei 2024 · Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders · Persbericht

15 mei 2024 · Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial · Persbericht

9 mei 2024 · Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights · Persbericht

9 mei 2024 · Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer · Persbericht

8 mei 2024 · Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference · Persbericht

30 april 2024 · Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights · Persbericht

25 april 2024 · Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting · Persbericht

Mijn selecties